Published in J Leukoc Biol on May 08, 2008
Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta (2010) 1.40
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci (2011) 1.37
The immune system and developmental programming of brain and behavior. Front Neuroendocrinol (2012) 1.36
Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol (2011) 1.22
Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr (2011) 1.12
MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation (2008) 1.07
Endocytic trafficking of chemokine receptors. Curr Opin Cell Biol (2013) 1.06
Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev Med Chem (2009) 1.03
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation (2010) 1.02
Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell Mol Life Sci (2013) 1.02
Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci (2011) 1.01
CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support. J Immunol (2012) 0.94
Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J Neuroimmunol (2012) 0.93
Systemic lipopolysaccharide compromises the blood-labyrinth barrier and increases entry of serum fluorescein into the perilymph. J Assoc Res Otolaryngol (2014) 0.92
CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function. J Leukoc Biol (2010) 0.90
Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain. Front Cell Neurosci (2014) 0.88
Increased micro-RNA 29b in the aged brain correlates with the reduction of insulin-like growth factor-1 and fractalkine ligand. Neurobiol Aging (2013) 0.88
Synaptic plasticity in the hippocampus shows resistance to acute ethanol exposure in transgenic mice with astrocyte-targeted enhanced CCL2 expression. Neuropharmacology (2012) 0.87
Functional defect of peripheral neutrophils in mice with induced deletion of CXCR2. Genesis (2013) 0.87
Dissecting the effects of endogenous brain IL-2 and normal versus autoreactive T lymphocytes on microglial responsiveness and T cell trafficking in response to axonal injury. Neurosci Lett (2012) 0.86
Transcriptomic analysis of the stress response to weaning at housing in bovine leukocytes using RNA-seq technology. BMC Genomics (2012) 0.86
The chemokine BRAK/CXCL14 regulates synaptic transmission in the adult mouse dentate gyrus stem cell niche. J Neurochem (2011) 0.84
Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. J Neuroimmunol (2012) 0.83
Immune responses to non-tumor antigens in the central nervous system. Front Oncol (2014) 0.83
Loss of CNS IL-2 gene expression modifies brain T lymphocyte trafficking: response of normal versus autoreactive Treg-deficient T cells. Neurosci Lett (2011) 0.82
(R)-(+)-α-lipoic acid protected NG108-15 cells against H₂O₂-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κβ-cytokines. Drug Des Devel Ther (2014) 0.79
Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis. PLoS One (2015) 0.79
Opposing roles for CXCR3 signaling in central nervous system versus ocular inflammation mediated by the astrocyte-targeted production of IL-12. Am J Pathol (2011) 0.79
Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia. Front Mol Neurosci (2016) 0.79
The expression of cytokines and chemokines in the blood of patients with severe weight loss from anorexia nervosa: an exploratory study. Cytokine (2014) 0.78
Loss of Neuronal Phenotype and Neurodegeneration: Effects of T Lymphocytes and Brain Interleukin-2. J Alzheimers Dis Parkinsonism (2013) 0.78
Adaptive immune response to viral infections in the central nervous system. Handb Clin Neurol (2014) 0.75
Sterile Neuroinflammation and Strategies for Therapeutic Intervention. Int J Inflam (2017) 0.75
Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol (2000) 14.74
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 11.41
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A (1994) 6.65
The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 5.45
Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science (1994) 5.20
Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol (1993) 5.16
Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science (1975) 5.13
Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol (2003) 4.76
Control of chemokine-guided cell migration by ligand sequestration. Cell (2008) 4.61
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Chemokines: immunology's high impact factors. Nat Immunol (2001) 3.36
Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol (2008) 3.04
What is immune privilege (not)? Trends Immunol (2006) 3.02
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci (2005) 2.61
Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol (2006) 2.53
What is the blood-brain barrier (not)? Trends Immunol (2006) 2.42
The chemokine SDF1a coordinates tissue migration through the spatially restricted activation of Cxcr7 and Cxcr4b. Curr Biol (2007) 2.35
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med (2008) 2.25
Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev Biol (2007) 2.24
Matrix metalloproteinases and diseases of the CNS. Trends Neurosci (1998) 2.24
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm (Vienna) (2006) 1.96
CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J Immunol (2000) 1.93
Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest (1994) 1.82
Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem (1993) 1.77
The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci (2005) 1.74
CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J Immunol (2001) 1.73
The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell (2002) 1.73
Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain (1999) 1.67
Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest (1999) 1.64
Neutrophils promote mononuclear cell infiltration during viral-induced encephalitis. J Immunol (2003) 1.60
Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol (1998) 1.60
Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev (2005) 1.59
Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem (2001) 1.58
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain (2005) 1.58
Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol (2007) 1.56
The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol (2001) 1.49
The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest (2007) 1.46
Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem (1997) 1.46
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology (1999) 1.42
CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr Biol (1998) 1.41
Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol (1997) 1.39
Pathways for internalization and recycling of the chemokine receptor CCR5. Blood (2002) 1.38
Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5. J Biol Chem (1997) 1.31
Lack of CCR2 results in increased mortality and impaired leukocyte activation and trafficking following infection of the central nervous system with a neurotropic coronavirus. J Immunol (2001) 1.27
Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion. Lab Invest (1981) 1.25
Perforin and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. J Virol (2004) 1.24
Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol (2002) 1.23
Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol (2000) 1.22
GRO family chemokines are specialized for monocyte arrest from flow. Am J Physiol Heart Circ Physiol (2005) 1.20
Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci (2007) 1.18
Ccr2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen. Cytokine (2002) 1.18
Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia (2006) 1.17
Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull (2003) 1.15
Regulation of chemotactic networks by 'atypical' receptors. Bioessays (2007) 1.14
The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation. J Neurosci (1998) 1.13
Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. J Virol (2005) 1.10
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood (2007) 1.09
The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol (2000) 1.07
Purification and biochemical characterization of the D6 chemokine receptor. Biochem J (2004) 1.07
Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. Eur J Immunol (2002) 1.06
Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis. J Immunol (2006) 1.04
Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res (1995) 1.02
Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol (2003) 1.01
Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection. J Virol (2002) 1.00
Murine experimental autoimmune encephalomyelitis: a model of immune-mediated inflammation and multiple sclerosis. Methods Enzymol (1997) 0.98
Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol (1998) 0.98
Enhanced expression of Duffy antigen in the lungs during suppurative pneumonia. J Histochem Cytochem (2003) 0.95
Expression of the duffy antigen/receptor for chemokines (DARC) by the inflamed synovial endothelium. J Pathol (2002) 0.94
Chemokine sequestration by atypical chemokine receptors. Biochem Soc Trans (2006) 0.92
Matrix metalloproteinases in multiple sclerosis: is it time for a treatment trial? Ann Neurol (2001) 0.76
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med (2013) 8.76
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab (2005) 6.85
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature (2011) 6.21
Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron (2012) 5.84
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology (2008) 3.99
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation (2013) 3.57
Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One (2010) 3.24
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol (2003) 2.58
Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron (2008) 2.44
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum (2007) 2.42
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity (2010) 2.32
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol (2010) 2.25
Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 2.24
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest (2012) 2.10
Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc (2006) 2.08
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol (2012) 2.01
The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol (2011) 1.96
Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke (2011) 1.91
The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke (2011) 1.90
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
Natalizumab and PML. Nat Neurosci (2005) 1.85
Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell (2009) 1.84
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83
G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood (2011) 1.82
Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood (2009) 1.81
Glutamine deamidation and dysfunction of ubiquitin/NEDD8 induced by a bacterial effector family. Science (2010) 1.77
The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci (2005) 1.74
The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell (2002) 1.73
Structure of a Shigella effector reveals a new class of ubiquitin ligases. Nat Struct Mol Biol (2008) 1.71
Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol (2002) 1.70
CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci (2010) 1.65
Genotyping of three candidate genes after whole-genome preamplification of DNA collected from buccal cells. Behav Genet (2003) 1.64
Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol (2007) 1.63
Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci (2011) 1.59
Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol (2006) 1.59
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain (2005) 1.58
Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol (2007) 1.56
Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke (2014) 1.53
Microgliosis: the questions shape the answers. Nat Neurosci (2007) 1.51
Cysteine methylation disrupts ubiquitin-chain sensing in NF-κB activation. Nature (2011) 1.50
Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J Clin Invest (2012) 1.50
A Legionella type IV effector activates the NF-kappaB pathway by phosphorylating the IkappaB family of inhibitors. Proc Natl Acad Sci U S A (2009) 1.48
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Role of gamma-glutamyl transpeptidase in redox regulation of K+ channel remodeling in postmyocardial infarction rat hearts. Am J Physiol Cell Physiol (2009) 1.45
Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol (2007) 1.45
Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol (2005) 1.45
Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J (2010) 1.44
Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci U S A (2012) 1.43
miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-β. Biochem Biophys Res Commun (2010) 1.42
Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev (2013) 1.40
The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta (2010) 1.40
Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. FASEB J (2011) 1.40
CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem (2011) 1.40
VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol (2004) 1.39
Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke (2011) 1.37
Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol (2011) 1.35
Structural mechanism of host Rab1 activation by the bifunctional Legionella type IV effector SidM/DrrA. Proc Natl Acad Sci U S A (2010) 1.35
Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics (2007) 1.34
Defining interferon beta response status in multiple sclerosis patients. Ann Neurol (2004) 1.34
Chemical probing reveals insights into the signaling mechanism of inflammasome activation. Cell Res (2010) 1.34
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci (2007) 1.31
Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev (2012) 1.30
Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J (2009) 1.30
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 1.29
A bacterial type III effector family uses the papain-like hydrolytic activity to arrest the host cell cycle. Proc Natl Acad Sci U S A (2009) 1.29
Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J Immunol Methods (2009) 1.29
Structural insights into the enzymatic mechanism of the pathogenic MAPK phosphothreonine lyase. Mol Cell (2007) 1.28
Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J Neurosci (2010) 1.28
Monocytes regulate T cell migration through the glia limitans during acute viral encephalitis. J Virol (2010) 1.27
CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol (2004) 1.26
Recurrent varicella zoster virus myelopathy. J Neurol Sci (2008) 1.26
Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol (2010) 1.26
Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. Hepatology (2009) 1.23
Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J Neurosci Res (2002) 1.23
A protective role for ELR+ chemokines during acute viral encephalomyelitis. PLoS Pathog (2009) 1.23